- Report
- January 2026
- 191 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- July 2024
- 288 Pages
Global
From €5187EUR$6,130USD£4,350GBP
- Report
- May 2023
- 169 Pages
Global
From €2058EUR$2,350USD£1,786GBP
- Report
- January 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP
- Report
- October 2023
- 78 Pages
United States
From €3065EUR$3,500USD£2,661GBP
- Report
- February 2024
- 87 Pages
Global
From €3500EUR$4,281USD£3,144GBP
Descovy is a combination drug used to treat HIV/AIDS. It is a combination of two drugs, emtricitabine and tenofovir alafenamide, and is used to reduce the amount of HIV in the body. It is taken as a single pill once a day and is used in combination with other antiretroviral drugs. Descovy is approved by the US Food and Drug Administration (FDA) for the treatment of HIV-1 infection in adults and adolescents aged 12 years and older.
Descovy is part of a larger market of HIV/AIDS drugs, which includes other antiretroviral drugs, such as Truvada, Atripla, and Genvoya. These drugs are used to reduce the amount of HIV in the body and to prevent the virus from replicating. They are also used to reduce the risk of HIV transmission.
The Descovy market is highly competitive, with many companies offering similar products. Some of the major players in the market include Gilead Sciences, Merck, ViiV Healthcare, and GlaxoSmithKline. Other companies in the market include Bristol-Myers Squibb, Janssen Pharmaceuticals, and Mylan. Show Less Read more
